X
X4 Pharmaceuticals, Inc. (XFOR)
NCM – Real Time Price. Currency in USD
4.34
-0.16 (-3.56%)
At close: May 12, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
4.34
-0.16 (-3.56%)
At close: May 12, 2026, 4:00 PM EDT
No Data
There are no news for this stock.
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 10.18 | 6.05 | 10 | |
| Quick ratio | 9.98 | 5.63 | 10 | |
| Debt to Equity | 0.46 | 0.30 | 7.0 | |
| Debt to Assets | 0.29 | 1.04 | 7.0 | |
| Interest coverage | -9.52 | -16.91 | 1.0 | |
| Weighted average score | 7.0 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | N/A | N/A | 3M | 35M | 9M |
| Gross Profit | -2M | -2M | 1M | 29M | 7M |
| Operating Income | -88M | -108M | -141M | -87M | -98M |
| Net Income | -94M | -101M | -37M | -79M | -100M |
| EBITDA | -86M | -106M | -141M | -86M | -97M |
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | 8.13 | 94.72 | 8.0 |
| Next quarter | 24.65 | 71.5 | 10 |
| Current year | -74.18 | 60.07 | 5.5 |
| Next year | 1.1 | -4.46 | 2.0 |
| Weighted average score | 6.4 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | 5.45 | 15.4 | 27.27 | 44.19 | 8.5 |
| Y/Y | -90.59 | -7277.65 | -499.99 | 53 | 3.3 |
| 3y average | 1090.4 | -18.74 | 65.45 | -8.72 | 5.5 |
| 5y average | 834.04 | -20.96 | 45.83 | -10.58 | 5.5 |
| Weighted average score | 5.7 | ||||
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |
Company's cash reserves $216.9M significantly exceed its total debt $77.3M, ensuring strong financial flexibility
Total current assets $242.0M exceed Total current liabilities $23.8M, highlighting excellent liquidity
Debt-to-equity ratio (0.5) is well below the industry average (0.3), showcasing prudent financial management
Interest coverage ratio (-9.5x) is dangerously low, suggesting debt repayment risks